Skip to main content

NASDAQ:INCY - Incyte Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $99.50
  • Forecasted Upside: 21.47 %
  • Number of Analysts: 17
  • Breakdown:
  • 1 Sell Ratings
  • 8 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$81.91
▼ -0.83 (-1.00%)
1 month | 3 months | 12 months
Get New Incyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INCY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$99.50
▲ +21.47% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $99.50, with a high forecast of $124.00 and a low forecast of $70.00. The average price target represents a 21.47% upside from the last price of $81.91.

Hold

The current consensus among 17 investment analysts is to hold stock in Incyte. This rating has held steady since March 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 12 buy ratings
  • 9 hold ratings
  • 1 sell ratings
11/17/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 9 hold ratings
  • 1 sell ratings
2/15/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 7 hold ratings
  • 1 sell ratings
5/15/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 8 hold ratings
  • 1 sell ratings
8/13/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 8 hold ratings
  • 1 sell ratings
11/11/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 8 hold ratings
  • 1 sell ratings
2/9/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 8 hold ratings
  • 1 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 1 sell ratings
5/10/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/5/2021Morgan StanleyLower Price TargetEqual Weight$86.00 ➝ $85.00Low
i
4/5/2021Morgan StanleyLower Price TargetEqual Weight$93.00 ➝ $86.00Low
i
2/10/2021Morgan StanleyLower Price TargetEqual Weight$97.00 ➝ $93.00Low
i
2/10/2021SVB LeerinkDowngradeMarket Perform ➝ Underperform$89.00 ➝ $70.00Low
i
1/7/2021TruistInitiated CoverageBuy$120.00N/A
i
1/4/2021GuggenheimUpgradeNeutral ➝ BuyN/A
i
11/9/2020Morgan StanleyLower Price TargetEqual Weight$103.00 ➝ $97.00High
i
11/6/2020BMO Capital MarketsLower Price TargetMarket Perform$94.00 ➝ $87.00Medium
i
11/6/2020Royal Bank of CanadaLower Price TargetSector Perform$96.00 ➝ $86.00Medium
i
10/15/2020Bank of AmericaLower Price TargetBuy$113.00 ➝ $110.00Low
i
10/13/2020Morgan StanleyBoost Price TargetEqual Weight$100.00 ➝ $103.00Low
i
8/9/2020CowenReiterated RatingBuyMedium
i
8/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$90.00 ➝ $94.00Low
i
8/6/2020Credit Suisse GroupLower Price TargetNeutral$100.00 ➝ $97.00Low
i
8/6/2020Morgan StanleyBoost Price TargetEqual Weight$95.00 ➝ $100.00Low
i
8/4/2020MizuhoInitiated CoverageHold$79.00 ➝ $95.00Medium
i
Rating by Mara Goldstein at Mizuho
8/4/2020SVB LeerinkBoost Price TargetMarket Perform$86.00 ➝ $87.00Low
i
8/3/2020Royal Bank of CanadaBoost Price TargetSector Perform$91.00 ➝ $92.00High
i
7/28/2020JPMorgan Chase & Co.Reiterated RatingHold$99.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
7/24/2020William BlairReiterated RatingBuyLow
i
Rating by Matt Phipps at William Blair
7/20/2020Credit Suisse GroupBoost Price TargetNeutral$88.00 ➝ $100.00High
i
7/17/2020OppenheimerReiterated RatingBuy$121.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
6/17/2020William BlairReiterated RatingBuyLow
i
Rating by Matt Phipps at William Blair
6/16/2020BenchmarkInitiated CoverageHoldLow
i
6/15/2020OppenheimerInitiated CoverageBuy$120.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
6/4/2020ArgusBoost Price TargetBuy$92.00 ➝ $124.00High
i
5/26/2020The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyHigh
i
5/19/2020Cantor FitzgeraldBoost Price TargetNeutral$83.00 ➝ $100.00Medium
i
5/12/2020Morgan StanleyBoost Price TargetEqual Weight$94.00 ➝ $95.00High
i
5/6/2020Credit Suisse GroupReiterated RatingHold$88.00Low
i
5/6/2020BMO Capital MarketsBoost Price TargetMarket Perform$74.00 ➝ $90.00Low
i
5/6/2020NomuraReiterated RatingBuy$116.00Low
i
5/6/2020OppenheimerBoost Price TargetOutperform$112.00 ➝ $120.00Medium
i
5/6/2020Royal Bank of CanadaBoost Price TargetIn-Line ➝ Sector Perform$81.00 ➝ $91.00Medium
i
5/5/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$89.00 ➝ $99.00Medium
i
4/29/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$94.00Medium
i
4/21/2020OppenheimerBoost Price TargetOutperform$90.00 ➝ $112.00Medium
i
4/20/2020Piper SandlerBoost Price TargetOverweight$95.00 ➝ $110.00Low
i
Rating by Tyler Van Buren at Piper Sandler
4/19/2020MizuhoReiterated RatingHold$79.00Low
i
Rating by Mara Goldstein at Mizuho
4/9/2020William BlairReiterated RatingBuyLow
i
Rating by Matt Phipps at William Blair
4/8/2020Royal Bank of CanadaReiterated RatingHold$81.00Medium
i
4/8/2020Nomura SecuritiesReiterated RatingBuy$116.00Medium
i
4/7/2020OppenheimerBoost Price TargetOutperform$85.00 ➝ $90.00Low
i
4/6/2020Piper SandlerReiterated RatingBuyHigh
i
Rating by Tyler Van Buren at Piper Sandler
4/1/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$83.00 ➝ $90.00Medium
i
3/25/2020OppenheimerLower Price Target$99.00 ➝ $85.00High
i
3/24/2020William BlairInitiated CoverageOutperformHigh
i
3/18/2020Royal Bank of CanadaReiterated RatingHold$81.00Medium
i
3/13/2020Bank of AmericaUpgradeNeutral ➝ Buy$83.00High
i
Rating by Tazeen Ahmad at Bank of America Co.
3/11/2020Credit Suisse GroupLower Price TargetNeutral$86.00 ➝ $81.00Medium
i
2/19/2020Piper SandlerReiterated RatingBuyLow
i
Rating by Tyler Van Buren at Piper Sandler
2/19/2020Nomura SecuritiesBoost Price TargetBuy$111.00 ➝ $116.00Low
i
2/19/2020CowenReiterated RatingBuyLow
i
Rating by Marc Frahm at Cowen Inc
2/16/2020JPMorgan Chase & Co.Reiterated RatingBuy$89.00Low
i
2/16/2020Evercore ISIReiterated RatingBuy$92.00Low
i
2/13/2020MizuhoReiterated RatingHold$79.00High
i
Rating by Mara Goldstein at Mizuho
2/4/2020Bank of AmericaReiterated RatingNeutral$82.00Low
i
1/30/2020Royal Bank of CanadaReiterated RatingHold$80.00Medium
i
1/27/2020Evercore ISIReiterated RatingBuy$92.00Low
i
1/23/2020Cantor FitzgeraldBoost Price TargetNeutral$65.00 ➝ $83.00Low
i
1/14/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
i
1/14/2020JMP SecuritiesReiterated RatingOutperform$121.00High
i
Rating by Reni Benjamin at JMP Securities
1/13/2020CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
1/6/2020Royal Bank of CanadaReiterated RatingHold ➝ NeutralHigh
i
1/6/2020Morgan StanleyLower Price TargetEqual Weight$89.00 ➝ $83.00Low
i
Rating by Matthew Harrison at Morgan Stanley
1/3/2020Royal Bank of CanadaLower Price Target$80.00Medium
i
1/3/2020The Goldman Sachs GroupLower Price TargetBuy$122.00 ➝ $107.00High
i
1/3/2020Credit Suisse GroupLower Price TargetNeutral$90.00 ➝ $86.00High
i
1/3/2020OppenheimerLower Price TargetOutperform$100.00 ➝ $96.00High
i
1/3/2020BMO Capital MarketsLower Price TargetMarket Perform$85.00 ➝ $74.00High
i
1/3/2020CitigroupReiterated RatingOutperform$100.00 ➝ $96.00High
i
1/3/2020JMP SecuritiesLower Price TargetMarket Outperform$110.00 ➝ $99.00High
i
Rating by Reni Benjamin at JMP Securities
1/3/2020Cantor FitzgeraldLower Price TargetNeutral$75.00 ➝ $65.00High
i
1/2/2020MizuhoDowngradeBuy ➝ Neutral$98.00 ➝ $79.00High
i
Rating by Mara Goldstein at Mizuho
1/2/2020Piper Jaffray CompaniesReiterated RatingBuy$95.00High
i
Rating by Tyler Van Buren at Piper Jaffray Companies
1/2/2020CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
1/2/2020GuggenheimDowngradeBuy ➝ NeutralMedium
i
Rating by Michael Schmidt at Guggenheim
12/18/2019MizuhoReiterated RatingBuy$98.00Low
i
Rating by Mara Goldstein at Mizuho
11/27/2019MizuhoReiterated RatingBuy$98.00Low
i
Rating by Mara Goldstein at Mizuho
10/29/2019MizuhoReiterated RatingBuy$95.00Medium
i
10/2/2019MizuhoInitiated CoverageBuy$95.00Medium
i
9/30/2019JMP SecuritiesBoost Price TargetBuy ➝ Market Outperform$107.00 ➝ $110.00Medium
i
Rating by Reni Benjamin at JMP Securities
9/27/2019CowenReiterated RatingBuyLow
i
Rating by Marc Frahm at Cowen Inc
9/27/2019GuggenheimSet Price TargetBuy$101.00Low
i
Rating by Michael Schmidt at Guggenheim
9/12/2019BMO Capital MarketsInitiated CoverageMarket Perform$85.00High
i
9/5/2019Morgan StanleyBoost Price TargetEqual ➝ Equal Weight$82.00 ➝ $87.00High
i
Rating by Matthew Harrison at Morgan Stanley
9/5/2019OppenheimerUpgradeMarket Perform ➝ Outperform$85.00 ➝ $100.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/5/2019JMP SecuritiesUpgradeMarket Perform ➝ Outperform$107.00Medium
i
8/4/2019CowenReiterated RatingBuyLow
i
Rating by Marc Frahm at Cowen Inc
7/31/2019SVB LeerinkSet Price TargetHold$90.00Medium
i
Rating by Andrew Berens at SVB Leerink LLC
7/31/2019Nomura SecuritiesBoost Price TargetBuy$100.00 ➝ $111.00Low
i
7/31/2019JPMorgan Chase & Co.Reiterated RatingBuy$91.00Low
i
7/31/2019Morgan StanleyBoost Price TargetEqual Weight$81.00 ➝ $82.00Low
i
6/17/2019Piper Jaffray CompaniesReiterated RatingBuyLow
i
Rating by Tyler Van Buren at Piper Jaffray Companies
5/27/2019CowenReiterated RatingBuyLow
i
Rating by Marc Frahm at Cowen Inc
5/20/2019Credit Suisse GroupInitiated CoverageNeutral$75.00Medium
i
5/15/2019Piper Jaffray CompaniesBoost Price TargetOverweight$85.00 ➝ $95.00Low
i
5/15/2019JPMorgan Chase & Co.Reiterated RatingBuy$90.00Low
i
5/3/2019BarclaysDowngradeOverweight ➝ Equal Weight$90.00 ➝ $82.00High
i
4/30/2019JPMorgan Chase & Co.Reiterated RatingBuyHigh
i
4/22/2019CowenReiterated RatingBuyLow
i
Rating by Marc Frahm at Cowen Inc
4/14/2019BarclaysReiterated RatingBuy$90.00High
i
4/10/2019Stifel NicolausInitiated CoverageHold$82.00 ➝ $82.00Medium
i
4/7/2019OppenheimerSet Price TargetHold$85.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/3/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$89.00High
i
2/25/2019ArgusBoost Price TargetBuy ➝ Buy$83.00 ➝ $98.00Low
i
Rating by Jasper Hellweg at Argus
2/15/2019Raymond JamesSet Price TargetBuy$100.00Low
i
Rating by Reni Benjamin at Raymond James
2/15/2019Royal Bank of CanadaBoost Price TargetOutperform$89.00High
i
2/11/2019JMP SecuritiesReiterated RatingHoldLow
i
2/5/2019SunTrust BanksBoost Price TargetBuy$90.00Low
i
1/24/2019William BlairUpgradeMarket Perform ➝ Outperform$85.00 ➝ $100.00Low
i
Rating by Y. Xu at William Blair
1/23/2019GabelliUpgradeHold ➝ Buy$105.00Medium
i
1/16/2019UBS GroupDowngradeBuy ➝ Neutral$75.00 ➝ $82.00Medium
i
1/15/2019The Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHigh
i
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
1/3/2019GuggenheimUpgradeNeutral ➝ BuyHigh
i
12/9/2018CowenReiterated RatingBuyLow
i
Rating by Marc Frahm at Cowen Inc
12/3/2018CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
10/30/2018JPMorgan Chase & Co.Set Price TargetBuy$88.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/30/2018CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
10/25/2018Raymond JamesReiterated RatingBuy$85.00Low
i
Rating by Reni Benjamin at Raymond James
10/21/2018Cantor FitzgeraldReiterated RatingNeutral ➝ Hold$73.00 ➝ $74.00Low
i
10/1/2018Cantor FitzgeraldInitiated CoverageNeutral ➝ Neutral$73.00Low
i
9/24/2018SVB LeerinkInitiated CoverageMkt Perform ➝ Market Perform$78.00Low
i
9/17/2018GuggenheimInitiated CoverageNeutralLow
i
9/15/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
9/13/2018OppenheimerSet Price TargetHold$70.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/4/2018CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
8/30/2018ArgusSet Price TargetBuy$83.00Low
i
Rating by Jasper Hellweg at Argus
8/15/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$74.00Low
i
8/1/2018JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
i
8/1/2018JPMorgan Chase & Co.Reiterated RatingBuy$88.00Medium
i
7/31/2018OppenheimerSet Price TargetHold$70.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/31/2018CowenReiterated RatingBuyHigh
i
Rating by Marc Frahm at Cowen Inc
7/27/2018Raymond JamesReiterated RatingBuyMedium
i
Rating by Reni Benjamin at Raymond James
7/17/2018OppenheimerSet Price TargetMarket Perform ➝ Hold$65.00 ➝ $70.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/13/2018Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
i
6/26/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$76.00 ➝ $74.00High
i
6/24/2018JPMorgan Chase & Co.Reiterated RatingBuy$88.00Medium
i
6/11/2018Evercore ISIUpgradeIn-Line ➝ Outperform$60.23 ➝ $140.11Medium
i
6/1/2018OppenheimerSet Price TargetHold$65.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/30/2018Piper Jaffray CompaniesInitiated CoverageBuy$85.00Low
i
Rating by Tyler Van Buren at Piper Jaffray Companies
5/2/2018CowenReiterated RatingBuyLow
i
5/1/2018OppenheimerSet Price TargetHold$65.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/1/2018Raymond JamesReiterated RatingBuyLow
i
Rating by Reni Benjamin at Raymond James
4/24/2018Raymond JamesReiterated RatingBuyHigh
i
Rating by Reni Benjamin at Raymond James
4/24/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$96.00 ➝ $88.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
4/23/2018OppenheimerSet Price TargetHold$65.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/17/2018Credit Suisse GroupSet Price TargetBuy$78.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
4/12/2018UBS GroupUpgradeNeutral ➝ Buy$76.00Low
i
Rating by Carter Gould at UBS Group AG
4/9/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$149.00 ➝ $96.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
4/9/2018Credit Suisse GroupLower Price TargetOutperform$146.00 ➝ $76.00High
i
Rating by Alethia Young at Credit Suisse Group AG
4/9/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$142.00 ➝ $76.00High
i
4/9/2018GabelliDowngradeBuy ➝ HoldMedium
i
Rating by J. He at Gabelli
4/9/2018Nomura SecuritiesLower Price TargetBuy$102.00Low
i
Rating by C. Marai at Nomura Securities
4/9/2018OppenheimerSet Price TargetHold$110.00 ➝ $65.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/6/2018Credit Suisse GroupSet Price TargetOutperform ➝ Outperform$145.00 ➝ $78.00Medium
i
Rating by Alethia Young at Credit Suisse Group AG
4/6/2018SunTrust BanksReiterated RatingBuy$80.00Low
i
4/6/2018Raymond JamesSet Price TargetBuy$85.00High
i
Rating by Reni Benjamin at Raymond James
4/6/2018GuggenheimReiterated RatingBuy ➝ NeutralHigh
i
4/6/2018William BlairReiterated RatingOutperform ➝ Market PerformHigh
i
Rating by Y. Xu at William Blair
4/5/2018BarclaysLower Price TargetOverweight ➝ Overweight$165.00 ➝ $135.00Low
i
2/28/2018Raymond JamesSet Price TargetBuy$159.00Medium
i
Rating by Reni Benjamin at Raymond James
2/20/2018OppenheimerSet Price TargetHold$110.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/15/2018Raymond JamesReiterated RatingBuyLow
i
Rating by Reni Benjamin at Raymond James
2/14/2018Credit Suisse GroupSet Price TargetBuy$145.00High
i
Rating by Alethia Young at Credit Suisse Group AG
2/1/2018Nomura SecuritiesReiterated RatingBuyHigh
i
Rating by C. Marai at Nomura Securities
1/22/2018OppenheimerReiterated RatingHold$120.00 ➝ $110.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/3/2018BMO Capital MarketsReiterated RatingBuy$172.00Low
i
1/2/2018CitigroupReiterated RatingMarket Perform$135.00 ➝ $120.00High
i
1/2/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$136.00High
i
Rating by Simos Simeonidis at Royal Bank of Canada
1/2/2018OppenheimerSet Price TargetHold$120.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold$106.00Medium
i
12/12/2017Raymond JamesReiterated RatingBuyMedium
i
Rating by Reni Benjamin at Raymond James
12/5/2017CowenReiterated RatingBuyLow
i
11/21/2017Royal Bank of CanadaLower Price TargetSector Perform ➝ Sector Perform$136.00 ➝ $120.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
10/31/2017OppenheimerSet Price TargetHold$135.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/31/2017BMO Capital MarketsBoost Price TargetOutperform$162.00 ➝ $166.00N/A
i
10/31/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/26/2017BMO Capital MarketsLower Price TargetOutperform$163.00 ➝ $162.00N/A
i
10/25/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
10/6/2017The Goldman Sachs GroupInitiated CoverageBuy$160.00N/A
i
10/6/2017Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Steven Desanctis at Jefferies Financial Group Inc.
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform$136.00Low
i
Rating by Simos Simeonidis at Royal Bank of Canada
9/13/2017ArgusReiterated RatingBuy$150.00Low
i
9/11/2017BMO Capital MarketsReiterated RatingOutperform$172.00 ➝ $163.00Low
i
9/11/2017Raymond JamesUpgradeMarket Perform ➝ Outperform$159.00High
i
Rating by Reni Benjamin at Raymond James
9/10/2017OppenheimerReiterated RatingHold$135.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/31/2017JPMorgan Chase & Co.Reiterated RatingBuy$149.00High
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
8/31/2017OppenheimerReiterated RatingHold$135.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/28/2017BMO Capital MarketsReiterated RatingOutperform$172.00Medium
i
8/16/2017Evercore ISIInitiated CoverageIn ➝ In-Line$135.00Medium
i
8/2/2017BarclaysReiterated RatingOverweight$180.00 ➝ $165.00Low
i
Rating by Paul Choi at Barclays PLC
8/1/2017JPMorgan Chase & Co.Set Price TargetBuy$149.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
7/27/2017Jefferies Financial GroupReiterated RatingBuy$148.00Medium
i
Rating by Steven Desanctis at Jefferies Financial Group Inc.
7/21/2017BMO Capital MarketsReiterated RatingBuy$172.00High
i
7/16/2017Credit Suisse GroupSet Price TargetBuy$152.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
7/4/2017Jefferies Financial GroupReiterated RatingBuy$165.00Medium
i
Rating by Steven Desanctis at Jefferies Financial Group Inc.
7/4/2017BarclaysBoost Price TargetOverweight$135.00 ➝ $185.00Medium
i
Rating by Paul Choi at Barclays PLC
7/3/2017CowenReiterated RatingOutperform$130.00Medium
i
6/28/2017GabelliReiterated RatingBuy$174.00Medium
i
6/20/2017Jefferies Financial GroupReiterated RatingBuy$148.00Medium
i
6/10/2017Credit Suisse GroupReiterated RatingBuyMedium
i
Rating by Alethia Young at Credit Suisse Group AG
6/6/2017OppenheimerSet Price TargetHold$135.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
6/6/2017BarclaysReiterated RatingOverweight$180.00Medium
i
Rating by Paul Choi at Barclays PLC
6/5/2017BMO Capital MarketsReiterated RatingOutperform$155.00 ➝ $166.00Medium
i
6/5/2017CowenReiterated RatingBuyMedium
i
5/31/2017CIBCBoost Price TargetOutperform$125.00 ➝ $135.00Low
i
5/31/2017OppenheimerReiterated RatingOutperform$125.00 ➝ $135.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/19/2017Morgan StanleyReiterated RatingOverweight$142.00Medium
i
5/18/2017OppenheimerSet Price TargetHold$125.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/18/2017JPMorgan Chase & Co.Set Price TargetBuy$149.00Medium
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
5/18/2017Jefferies Financial GroupReiterated RatingBuy$148.00Low
i
5/15/2017CowenReiterated RatingBuyN/A
i
5/15/2017BMO Capital MarketsBoost Price TargetOutperform$144.00 ➝ $146.00N/A
i
5/12/2017CIBCReiterated RatingMarket Perform ➝ Market Perform$125.00Low
i
5/12/2017OppenheimerInitiated CoverageMarket Perform$125.00Medium
i
5/9/2017Credit Suisse GroupSet Price TargetOutperform$167.00 ➝ $152.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
5/5/2017BMO Capital MarketsBoost Price TargetOutperform$144.00 ➝ $146.00Low
i
5/5/2017CowenReiterated RatingBuyHigh
i
4/19/2017SunTrust BanksLower Price TargetBuy$160.00 ➝ $145.00Low
i
4/19/2017BMO Capital MarketsLower Price TargetOutperform$170.00 ➝ $144.00High
i
4/19/2017Credit Suisse GroupSet Price TargetBuy$167.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
4/19/2017BarclaysLower Price TargetOverweight$185.00 ➝ $180.00Low
i
Rating by Paul Choi at Barclays PLC
4/18/2017Credit Suisse GroupReiterated RatingOutperform$174.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
4/18/2017Morgan StanleyBoost Price TargetOverweight$130.00 ➝ $150.00Low
i
4/18/2017The Goldman Sachs GroupLower Price TargetBuy$149.00 ➝ $136.00Low
i
4/17/2017Raymond JamesReiterated RatingHoldHigh
i
Rating by Reni Benjamin at Raymond James
4/17/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$165.00 ➝ $148.00Low
i
4/17/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Neutral$124.00Medium
i
4/10/2017GabelliInitiated CoverageBuy ➝ Buy$185.00Medium
i
4/8/2017BarclaysSet Price TargetBuy$135.00Medium
i
Rating by Paul Choi at Barclays PLC
4/7/2017BarclaysBoost Price TargetOverweight$135.00 ➝ $185.00Low
i
4/6/2017Raymond JamesDowngradeOutperform ➝ HoldMedium
i
Rating by Reni Benjamin at Raymond James
4/6/2017Jefferies Financial GroupReiterated RatingBuy$165.00Medium
i
4/5/2017Raymond JamesReiterated RatingOutperform ➝ Market Perform$135.00Medium
i
4/5/2017UBS GroupDowngradeOutperform ➝ Market PerformN/A
i
Rating by Carter Gould at UBS Group AG
4/4/2017Royal Bank of CanadaBoost Price TargetOutperform$138.00 ➝ $157.00Low
i
Rating by Simos Simeonidis at Royal Bank of Canada
4/3/2017BMO Capital MarketsBoost Price TargetOutperform$140.00 ➝ $170.00Medium
i
4/3/2017CowenReiterated RatingOutperformHigh
i
3/31/2017Royal Bank of CanadaReiterated RatingOutperform ➝ Buy$138.00High
i
3/21/2017William BlairInitiated CoverageOutperformLow
i
Rating by Y. Xu at William Blair
3/9/2017UBS GroupInitiated CoverageNeutral ➝ Neutral$140.00N/A
i
3/8/2017CowenReiterated RatingOutperformMedium
i
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$148.00N/A
i
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
i
2/21/2017Jefferies Financial GroupReiterated RatingBuy$140.00N/A
i
2/16/2017BMO Capital MarketsReiterated RatingOutperform$135.00 ➝ $149.00N/A
i
2/16/2017JPMorgan Chase & Co.Reiterated RatingBuy$136.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
2/15/2017Jefferies Financial GroupBoost Price TargetBuy$136.00 ➝ $140.00N/A
i
2/15/2017Royal Bank of CanadaBoost Price TargetOutperform$123.00 ➝ $138.00N/A
i
2/14/2017Royal Bank of CanadaReiterated RatingOutperform$123.00 ➝ $138.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
1/27/2017The Goldman Sachs GroupBoost Price TargetBuy$116.00 ➝ $149.00N/A
i
1/23/2017Credit Suisse GroupInitiated CoverageOutperform$137.00N/A
i
1/19/2017BarclaysBoost Price TargetBuy$105.00 ➝ $135.00N/A
i
1/18/2017JMP SecuritiesReiterated RatingOutperform$130.00N/A
i
1/12/2017CowenReiterated RatingOutperformN/A
i
1/10/2017BMO Capital MarketsReiterated RatingBuy$122.00 ➝ $135.00N/A
i
12/6/2016BMO Capital MarketsReiterated RatingOutperform$126.00N/A
i
12/5/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
11/20/2016SVB LeerinkReiterated RatingOutperform$101.00 ➝ $115.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
11/19/2016BMO Capital MarketsReiterated RatingOutperform$121.00 ➝ $126.00N/A
i
Rating by Ian Somaiya at BMO Capital Markets
11/8/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
11/3/2016JPMorgan Chase & Co.Reiterated RatingBuy$101.00N/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
11/2/2016SVB LeerinkReiterated RatingOutperform$99.00 ➝ $101.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
10/24/2016Royal Bank of CanadaSet Price TargetBuy$113.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
10/12/2016Royal Bank of CanadaSet Price TargetBuy$113.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
10/12/2016SVB LeerinkReiterated RatingOutperform$98.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
10/12/2016CowenReiterated RatingOutperformN/A
i
Rating by Eric Schmidt at Cowen Inc
10/12/2016Royal Bank of CanadaBoost Price TargetOutperform$106.00 ➝ $113.00N/A
i
10/10/2016JMP SecuritiesBoost Price TargetMarket Outperform$100.00 ➝ $110.00N/A
i
Rating by Liisa Bayko at JMP Securities
10/10/2016Royal Bank of CanadaReiterated RatingOutperform$116.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
10/7/2016BMO Capital MarketsBoost Price TargetOutperform$100.00 ➝ $121.00N/A
i
Rating by Ian Somaiya at BMO Capital Markets
10/3/2016SVB LeerinkBoost Price TargetOutperform$95.00 ➝ $98.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
9/29/2016Raymond JamesUpgradeMarket Perform ➝ Outperform$115.00N/A
i
9/28/2016Piper Jaffray CompaniesSet Price TargetBuy$99.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
9/28/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
9/28/2016Royal Bank of CanadaReiterated RatingOutperform$116.00N/A
i
9/26/2016ArgusBoost Price TargetBuy$92.00 ➝ $98.00N/A
i
8/16/2016Piper Jaffray CompaniesSet Price TargetBuy$99.00 ➝ $102.00N/A
i
Rating by joshua schimmer at Piper Jaffray Companies
8/10/2016Jefferies Financial GroupReiterated RatingBuy$98.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
8/10/2016BarclaysBoost Price TargetOverweight$85.00 ➝ $100.00N/A
i
8/10/2016SVB LeerinkBoost Price TargetOutperform$85.00 ➝ $95.00N/A
i
Rating by Michael Schmidt at SVB Leerink LLC
8/5/2016SunTrust BanksInitiated CoverageBuy$105.00N/A
i
8/1/2016Piper Jaffray CompaniesReiterated RatingBuy$76.00 ➝ $102.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
7/18/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Michael Schmidt at SVB Leerink LLC
7/12/2016Royal Bank of CanadaInitiated CoverageOutperform$105.00N/A
i
6/29/2016The Goldman Sachs GroupReiterated RatingBuyN/A
i
6/15/2016JMP SecuritiesReiterated RatingOutperform$100.00N/A
i
6/7/2016BMO Capital MarketsReiterated RatingBuy$91.00 ➝ $97.00N/A
i
Rating by Ian Somaiya at BMO Capital Markets
6/6/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Jonathan Aschoff at Brean Capital
5/19/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by Andrew Berens at Morgan Stanley
5/10/2016OppenheimerReiterated RatingBuyN/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
5/10/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by Andrew Berens at Morgan Stanley
5/10/2016Brean CapitalReiterated RatingBuy$92.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
5/10/2016Jefferies Financial GroupReiterated RatingBuy$88.00N/A
i
Rating by Brian Abrahams at Jefferies Financial Group Inc.
(Data available from 5/10/2016 forward)
Incyte logo
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $81.91
$81.58
$83.50

50 Day Range

MA: $82.35
$78.25
$85.61

52 Week Range

Now: $81.91
$75.52
$110.36

Volume

31,360 shs

Average Volume

1,259,251 shs

Market Capitalization

$18.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Incyte?

The following equities research analysts have issued research reports on Incyte in the last twelve months: Argus, Bank of America Co., Benchmark Co., BMO Capital Markets, Cantor Fitzgerald, Cowen Inc, Credit Suisse Group AG, Guggenheim, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Oppenheimer Holdings Inc., Royal Bank of Canada, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Truist, and William Blair.
View the latest analyst ratings for INCY.

What is the current price target for Incyte?

12 Wall Street analysts have set twelve-month price targets for Incyte in the last year. Their average twelve-month price target is $99.50, suggesting a possible upside of 21.7%. Argus has the highest price target set, predicting INCY will reach $124.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $70.00 for Incyte in the next year.
View the latest price targets for INCY.

What is the current consensus analyst rating for Incyte?

Incyte currently has 1 sell rating, 8 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INCY, but not buy more shares or sell existing shares.
View the latest ratings for INCY.

What other companies compete with Incyte?

How do I contact Incyte's investor relations team?

Incyte's physical mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company's listed phone number is 302-498-6700 and its investor relations email address is [email protected] The official website for Incyte is www.incyte.com.